YES1 and neoplasm: As shown in Fig. 6A, Yes1 overexpression significantly enhanced ovarian tumour growth and induced cisplatin resistance, with a slower tumour growth curve and slower tumour growth volume after cisplatin injection intraperitoneally in the YES1-NC group than in the YES1-OE group (Fig. 6B).